Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514381 | 1.00 | ADORA2A (0.37) | ADORA2AADORA2BTSHR | |
| SCHEMBL14746268 | 0.85 | JAK2 (0.36) | — | |
| SCHEMBL30506272 | 0.72 | ADORA2A (0.38) | ADORA2AADORA2BTSHR | |
| SCHEMBL3150981 | 0.72 | ADORA2A (0.38) | ADORA2AADORA2BTSHR | |
| SCHEMBL5681952 | 0.71 | ADORA2A (0.53) | ADORA2AADORA2B | |
| SCHEMBL14070089 | 0.71 | GRM4 (0.39) | ADORA2AADORA2BTSHR | |
| SCHEMBL30806243 | 0.71 | GRM4 (0.39) | ADORA2AADORA2BTSHR | |
| SCHEMBL19230708 | 0.69 | TGFBR1 (0.35) | — | |
| SCHEMBL13122059 | 0.69 | ADORA2A (0.52) | ADORA2AADORA2BTSHR | |
| SCHEMBL14634300 | 0.69 | TGFBR1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| EP-4214214-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-07-26 | — | — | EP | disclosed |
| CN-116171280-A | Casein kinase 1 delta modulators | 詹森药业有限公司 | 2023-05-26 | — | — | CN | disclosed |
| WO-2022058920-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-24 | — | — | WO | disclosed |
| EP-2751106-B1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER IP GMBH (DE) | 2017-10-18 | — | — | EP | disclosed |
| WO-2013030288-A1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK1G1 | ADORA2A 3319/4885ADORA2B 3351/4885TSHR 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.